Lupin Limited based in Mumbai, India, was founded in 1968 and since then it has grown vigorously and become a transnational pharmaceutical company. It is one of the largest manufacturers of high-quality medications that participates in the development and promotion of many active pharmaceutical ingredients (API), brand name and generic drugs.
Lupin Limited has research-and-development centers in India, Japan and the United States with over 1,400 scientists developing new chemical and herbal substances, creating brand new medications and generic drugs. The company’s products are exported to over 70 countries in Europe, North and South America, Africa, Australia and Asia. Lupin Limited is in the TOP-5 of the fastest growing and largest pharmaceutical companies producing generics in South Africa.
The priority therapeutic areas of the company include antibiotic agents from the class of drugs known as cephalosporins, antituberculosis drugs, ACE inhibitors, nonsteroidal antiinflammatory drugs, food additives and statins (Lovastatin, Simvastatin). The company’s portfolio contains almost full range of anti-TB and antiasthmatic medications. Moreover, Lupin is the leading manufacturer of anti-TB drugs – it accounts for about 80% of the global production of Ethambutol, 40% of Rifampicin and 30% of Pyrazinamide; these molecules are the company’s top selling ones.
The company has offices in the United Kingdom of Great Britain, Japan, Russia, Singapore, and it has created a subsidiary in the USA – Lupin Pharmaceuticals Inc. Suprax (for the use in pediatrics) was the first brand drug developed by Lupin Pharmaceuticals in the US. The company first entered the US market of generic preparations in 2003 when the U.S. Food and Drug Administration approved its application for Cefuroxime axetil, a generic version of an antibiotic sold under the brand name Ceftin (GlaxoSmithKline). Since then Lupin Pharmaceuticals has brought a lot of other generic preparations, mainly cephalosporin antibiotics (Cephalexin), to the US market of generics. Lupin is the 5th fastest growing and largest player in the US generics market. The company is also one of the top five generic drug manufacturers represented in the USA market when it comes to number of prescriptions. It is the market leader in 28 out of the 77 medications it offers in the generics market of the US.
Official website of Lupin Limited: www.lupin.com